Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model

Aaron N Long1,2, Katrina Owens1, Anna E Schlappal3,6, Tibor Kristian1,4, Paul S Fishman2,5 and Rosemary A Schuh1,2*

Abstract

Background: Mitochondrial dysfunction is a hallmark of neurodegenerative diseases including Alzheimer’s disease (AD), with morphological and functional abnormalities limiting the electron transport chain and ATP production. A contributing factor of mitochondrial abnormalities is loss of nicotinamide adenine dinucleotide (NAD), an important cofactor in multiple metabolic reactions. Depletion of mitochondrial and consequently cellular NAD(H) levels by activated NAD glycohydrolases then culminates in bioenergetic failure and cell death. De Novo NAD+ synthesis from tryptophan requires a multi-step enzymatic reaction. Thus, an alternative strategy to maintain cellular NAD+ levels is to administer NAD+ precursors facilitating generation via a salvage pathway. We administered nicotinamide mononucleotide (NMN), an NAD+ precursor to APPswe/PS1ΔE9 double transgenic (AD-Tg) mice to assess amelioration of mitochondrial respiratory deficits. In addition to mitochondrial respiratory function, we examined levels of full-length mutant APP, NAD+-dependent substrates (SIRT1 and CD38) in homogenates and fission/fusion proteins (DRP1, OPA1 and MFN2) in mitochondria isolated from brain. To examine changes in mitochondrial morphology, bigenic mice possessing a fluorescent protein targeted to neuronal mitochondria (CaMK2a-mito/eYFP), were administered NMN.

Methods: Mitochondrial oxygen consumption rates were examined in N2A neuroblastoma cells and non-synaptic brain mitochondria isolated from mice (3 months). Western blotting was utilized to assess APP, SIRT1, CD38, DRP1, OPA1 and MFN2 in brain of transgenic and non-transgenic mice (3–12 months). Mitochondrial morphology was assessed with confocal microscopy. One-way or two-way analysis of variance (ANOVA) and post-hoc Holm-Sidak method were used for statistical analyses of data. Student t-test was used for direct comparison of two groups.

Results: We now demonstrate that mitochondrial respiratory function was restored in NMN-treated AD-Tg mice. Levels of SIRT1 and CD38 change with age and NMN treatment. Furthermore, we found a shift in dynamics from fission to fusion proteins in the NMN-treated mice.

Conclusions: This is the first study to directly examine amelioration of NAD+ catabolism and changes in mitochondrial morphological dynamics in brain utilizing the immediate precursor NMN as a potential therapeutic compound. This might lead to well-defined physiologic abnormalities that can serve an important role in the validation of promising agents such as NMN that target NAD+ catabolism preserving mitochondrial function.

Keywords: Alzheimer’s disease, Mitochondria, Nicotinamide adenine dinucleotide, Nicotinamide mononucleotide, Neurodegeneration

* Correspondence: rschuh@som.umaryland.edu
1 Research Service, VAMHCS, 10 North Greene Street, Baltimore, MD 21201, USA
2 Department of Neurology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA
Full list of author information is available at the end of the article

© 2015 Long et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, with aging being the most important risk factor [1]. Mitochondrial dysfunction is a hallmark of neurodegenerative diseases with morphological and functional abnormalities limiting the electron transport chain and adenosine triphosphate (ATP) production seen in AD [2].

Nicotinamide adenine dinucleotide (NAD) is a cofactor that is essential for many biological reactions in either its oxidized (NAD⁺) or reduced (NADH) forms [3]. NAD⁺ and NADH mediate transfer of hydrogens in oxidative and reductive metabolic reactions [4]. NAD⁺ is essential to many mitochondrial enzymatic reactions and appropriate cellular bioenergetic metabolism [5,6]. NAD⁺ levels naturally decline with aging [4]. In normal conditions, the loss of NAD⁺ inhibits cellular respiration, resulting in loss of mitochondrial ATP production and potentially cellular death [5]. NAD⁺ is used as a substrate by several NAD⁺ dependent enzymes including poly(ADP-ribose) polymerase 1 (PARP1), Sirtuin 1 (SIRT1), and ADP-ribosyl cyclase (CD38) [4,5,7,8].

Preventing NAD⁺ depletion and cellular energy deficits could be a therapeutic target for neurodegenerative diseases and act as a neuroprotective mechanism [7]. Four pathways can synthesize NAD⁺ in mammals. NAD⁺ can be synthesized from the salvage pathway (primary route) utilizing nicotinamide, nicotinic acid, nicotinamide riboside, or the de novo pathway using tryptophan [9]. Nicotinamide phosphoribosyltransferase (Nampt) helps transfer a phosphoribosyl residue to nicotinamide forming nicotinamide mononucleotide (NMN) [9]. NAD⁺ consists of NMN covalently bound to adenosine monophosphate (AMP) [4]. The enzyme NMN adenyltransferase (NMNAT) converts NMN to NAD⁺ in one step [4,9,10] making NMN a key precursor with possible therapeutic implications for increased NAD⁺ levels [11,12]. Further, NMN is more soluble than NAD⁺ in phosphate buffered saline (PBS) and is taken up more efficiently through the plasma membrane [9,13].

We have recently demonstrated in the well-studied AD chimeric APPswe/PS1ΔE9 mouse model, deficits in mitochondrial oxygen consumption rates (OCR) in both brain and muscle [14]. These deficits in OCR may have resulted from lack of sufficient NAD⁺ due to increased catabolism. Thus, in the present study we tested the hypothesis that increasing NAD⁺ availability by administering the precursor NMN would reverse mitochondrial OCR deficiencies in these AD disease-relevant animals. Mitochondrial respiration, calcium homeostasis and organelle transport have also been demonstrated to be influenced by mitochondrial morphology [15,16].

Fusion of two mitochondria causes an elongated morphology that can play a protective role in the nervous system, while fission allows proper distribution of mitochondria and is also used to remove damaged organelles [17]. Mitochondrial dynamics are the balance of fission and fusion, controlling the morphology, number, and function of mitochondria [17-19]. Abnormal changes in these dynamics have been linked with aging and several neurodegenerative diseases (e.g. AD, Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS)). In these diseases mitochondrial morphology tends to shift towards increased fragmentation, indicating either an increase in fission or decreased fusion [19]. To examine changes in mitochondrial morphology, bigenic mice possessing a fluorescent protein targeted to neuronal mitochondria (CaMK2a-mito/eYFP), were administered NMN.

We demonstrate restoration of OCR in the NMN-treated AD double transgenic (AD-Tg) mice, indicating NAD⁺ levels were probably limiting. To further evaluate the basis of this effect we measured immunoreactivity of the NAD⁺-consuming proteins SIRT1 and CD38 and determined that they change with age as well as a function of NMN-treatment. Furthermore, we found a shift in dynamics from fission to fusion proteins in the NMN treated mice. This is the first study to directly examine amelioration of NAD⁺ catabolism and changes in mitochondrial morphological dynamics in AD mouse brain utilizing the immediate precursor NMN as a potential therapeutic compound.

Methods

Chemicals

All chemicals were purchased from Sigma-Aldrich (St Louis, MO) unless otherwise stated.

Animals

**Alzheimer’s disease-relevant mice**

Double transgenic mice expressing a chimeric mouse/human amyloid precursor protein (APP) with the Swedish mutation (APPswe) and a mutant human presenilin 1 (PS1) with the delta E9 (PS1ΔE9) (strain # 005864) and wildtype C57BL/6 mice were purchased from the Jackson Laboratory, (Bar Harbor, ME). AD animals positive for the transgenes were identified by polymerase chain reaction (PCR) using genomic DNA, isolated from the tails (Qiagen, Valencia, CA) then processed as described previously [14].

**CaMKIIα-tTA and pTRE-mito/eYFP mice**

Transgenic mice expressing the tetracycline-controlled transactivator protein (tTA) under regulatory control of the calcium/calmodulin-dependent kinase II (CaMKII) promoter [20] and animals expressing pTRE-mito/eYFP [21] were purchased from the Jackson Laboratory. Bigenic mice positive for both CaMKIIα-tTA and pTRE-mito/eYFP (CaMK2a-mito/eYFP) were generated...
by crossing these two strains. Male and female bigenic mice (2 months) were used in this study. CaMK2a-mito/eYFP bigenic mice were identified by PCR as described previously [21]. The University of Maryland School of Medicine Institutional Animal Use and Care Committee approved all procedures involving animal care, euthanasia and tissue collection.

Nicotinamide mononucleotide (NMN) administration

APP(swe)/PS1ΔE9 and CaMK2a-mito/eYFP male and female mice (2 months) were administered NMN (100 mg/kg, Sigma N3501) in sterile PBS (200 μl) subcutaneously (in the loose skin around the neck and shoulder area) every other day for 28 days. Non-transgenic (NTG) and vehicle control animals were administered 200 μl sterile PBS subcutaneously every other day for 28 days. Subcutaneous administration was utilized based on pilot studies. No significant differences in weight or external characteristics (fur condition, energy, size etc.) were observed between NMN and vehicle treated mice (data not shown).

N2A neuroblastoma cell culture conditions

Low passage mouse N2A hippocampal neuroblastomas (ATCC, Manassas, VA; 5,000/well) were seeded on V7 microplates (Seahorse Bioscience, North Billerica, MA) in proliferation media ((MEM, (ATCC), 10% fetal bovine serum, (Gibco, Grand Island, NY), 1% Pen-Strep, (Gibico)) and maintained in a humidified incubator at 37°C and 5% CO2. After 24 h, cultures were transiently transfected (see below). After a further 24 hours, the proliferation media was replaced with differentiation media (DM) consisting of MEM, 2% horse serum (Gibco) and 1% Pen-Strep. The cultures had media changes using DM 48 hours later and oxygen consumption rates were measured 24 hours later. All wells were critically examined under the microscope to ensure cell viability prior to performing experiments.

Plasmid vector generation and transfection

The plasmid vector containing cDNA for a mitochondrially-targeted enhanced yellow fluorescent protein (eYFP), mutant APP(swe) and mutant PS1ΔE9 described in [14] possesses a tetracycline response element thus requiring co-transfection with a tetracycline transactivator (TTA, Clontech). Co-transfection gives rise to cells possessing eYFP targeted to mitochondria and transgene-derived APP and PS1. N2A neuroblastomas were co-transfected with both constructs or TTA alone (control transfection) utilizing 1 μg of DNA/construct/well using the Magnetofection system (Oz Biosciences, San Diego, CA) with CombiMag plus lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.

Isolation of non-synaptic brain mitochondria

Twenty-four hours after the final NMN or vehicle injections, male and female APP(swe)/PS1ΔE9 or non-transgenic mice (3 months) were decapitated, forebrains rapidly removed and placed in ice-cold mannitol-sucrose (MS) buffer pH 7.4 (225 mM mannitol, 75 mM sucrose, 5 mM Heps, 1 μM fatty acid free BSA (Roche Diagnostics, Indianapolis, IN), 1 mM EGTA). Forebrains were homogenized with 10 strokes using a Potter-Elvehjem tissue grinder (Wheaton Science Products, Millville, NJ). The brain homogenates were further processed using the Percoll isolation method described by [22] and as used previously [14,23]. This method has been demonstrated to show a high level of mitochondrial purity by electron microscopy [23]. Protein concentrations were determined by the method described by [24] using BSA as standards. Aliquots of brain mitochondria and homogenate had protease inhibitors (Calbiochem, San Diego, CA) added prior to storage at −20°C for later Western blot analyses.

N2A neuroblastoma cell respirometry

Prior to measurements, cultures were gently rinsed in pre-warmed (37°C) assay measurement buffer (MB) consisting of 120 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl2, 0.4 mM KH2PO4, 1 mM MgCl2, 5 mM HEPES (pH 7.4) supplemented with 2.5 mM D-glucose. The cells were then placed in an unbuffered, humidified incubator at 37°C for 2 hours to allow temperature and pH equilibration. Cells were visually inspected prior to and after MB addition then loaded onto the Seahorse XF24-3 flux analyzer (Seahorse Bioscience). After an equilibration step, basal oxygen consumption rates (OCR, pMoles/min) were recorded using 3-min mix, 2-min wait, and 3-min measure (looped 3 times) cycles prior to injection of oligomycin to inhibit the ATP synthase. Three more measurement loops were recorded prior to injection of carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) to induce maximal oxygen consumption. Following recording of 3 more measurement loops, pyruvate was injected to determine if maximal oxygen consumption following FCCP addition was substrate limited. Antimycin A (inhibitor of mitochondrial respiration) was injected after 3 measurement loops to assess non-mitochondrial OCR. Two measurement loops were recorded after antimycin A injection then the experiment was terminated. The injectates prepared in MB (75 μl volumes) were preloaded, then sequentially injected as indicated through ports in the XF24 calibration cartridge to final concentrations of 1 μg/ml oligomycin, 1 μM FCCP, 10 mM pyruvate, and 1 μM antimycin A. Each plate had a subset of cells incubated with 10 mM nicotinamide adenine dinucleotide (NAD+, during the DM pre-incubation) prior to measurements.
Brain mitochondrial respirometry
Following calibration of the Seahorse XF24-3 flux analyzer (Seahorse Bioscience), the final non-synaptic mitochondrial pellets from individual mouse brains were resuspended in MAS1 buffer [25] and 5 μg protein as determined above [24] loaded into each of 20 wells of an XF24 V7 cell culture plate (Seahorse Bioscience). The plates were centrifuged at 1,600 × g at 4°C for 5 min. MAS1 buffer with 5 mM L-malate plus 5 mM sodium pyruvate (freshly made in MAS1 buffer) was gently added to the wells and the plates immediately loaded onto the instrument and oxygen consumption measurements were recorded as previously described [14]. All measurements were performed at 37°C.

Immunoblotting
Proteins as determined by [24] from brain homogenates or non-synaptic mitochondria (50 μg of APPΔE9/PS1ΔE9) and their non-transgenic litter mates (3 months) were resolved using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on precast Mini-Protean TGX any KD gels (Bio-Rad, Hercules, CA) and transferred to a polyvinylidene difluoride membrane using a Trans-Blot Turbo transfer system (Bio-Rad). Immunoblotting was performed according to Li-Cor Biosciences (Lincoln, NE) protocol. Briefly, nonspecific sites were blocked in non-mammalian blocking buffer (Li-Cor Biosciences). After blocking, the membranes were incubated with primary antibodies to Beta amyloid 1–16 (6E10, 1:1,000; Covance); Histone deacetylase sirtuin 1 (SIRT1, 1:500; Millipore); NAD+ glycohydrolase CD38 (CD38; 1:2,000; R&D, Minneapolis, MN); Dynamin-related protein 1 (DRP1, 1:1,000; BD Biosciences, San Jose, CA); Phospho-DRP1 (P[Ser616]-DRP1, 1:1,000; Cell Signaling Technology, Danvers, MA); Mitofusin 2 (MFN2, 1:1,000; Abcam, Cambridge, MA); Optic atrophy protein (OPA1, 1:1,000; BD Biosciences); Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:14,000; Cell Signaling Technology); Voltage dependent anion channel (VDAC, 1:1,000; rabbit); Cell Signaling Technology); VDAC (mouse; 1:1,000; Mitosciences (Eugene, OR); β-Actin (1:10,000; Sigma) at 4°C overnight. After 4 × 5 min washes in phosphate buffered saline (PBS) with 0.1% tween-20 (PBST), the membranes were incubated in the appropriate infrared (IR) fluorescent conjugated secondary antibody (Li-Cor Biosciences) for 30 min in the dark. Following PBST washes, the IR signal was captured on an Odyssey infrared imaging system (Li-Cor Biosciences) and stored as a digital image. VDAC was utilized as the loading control for mitochondria and GAPDH or β-Actin for brain homogenate to ensure equal loading.

Histology
Male and female CaMK2a-mito/eYFP, (3 months) were perfusion-fixed under deep anesthesia then processed as previously described [26].

Laser scanning confocal microscopy and quantitation of mitochondrial morphology
Forty μm-thick coronal brain tissue sections from CaMK2a-mito/eYFP mice (3 months) were washed with potassium phosphate buffered saline (KPBS) then mounted and coverslipped using Vectashield Hard set (Vector, Burlingame, CA) mounting media. Mitochondria in brain sections from CA1 hippocampal sub-regions were imaged utilizing a Zeiss LSM 510 laser scanning confocal microscope using a Plan-Apochromat 63x/1.4 oil lens. Single planes of 1024 × 1024 pixels were recorded at 1.0 – 1.5 Airy unit pinhole every 0.2 μm z-spacing throughout the entire tissue section as previously described [26] with modifications. Specifically, z-stack images were obtained from the striatum oriens of the CA1 sub-region. A 488 nm laser was used to visualize eYFP. Four z-stack images were taken per mouse brain. Recorded images were analyzed with Volocity software (Perkin Elmer, Waltham, MA). Quantification of mitochondrial morphology utilizing Volocity software was performed as previously described [26]. The following equation was used to determine 3D shape factor (ratio of the surface area of a sphere (with the same volume as the given object) to the surface area of the object): 

\[ V_{0} = \text{volume of object}; \ A_{0} = \text{area of object} \]

\[ 3D \text{ Shape Factor} = \frac{\pi^{1/3} (6V_0)^{2/3}}{A_0} \]

Statistical analysis
Data are expressed as means ± SE, and the comparisons between experimental groups were made with SPSS statistical software (SPSS, Inc., Chicago, IL) using analysis of variance (ANOVA). Posthoc Holm-Sidak method was used for all pairwise comparisons after ANOVA tests. Student t-test was used when direct comparison of two groups were analyzed (volocity data). Significance was assumed at p < 0.05.

Results
Exogenous NAD+ reverses deficient oxygen consumption rates (OCR) in a cell-based model of amyloid beta toxicity
N2A hippocampal neuroblastoma cells were transiently co-transfected with constructs containing mutant APPΔE9/PS1ΔE9 and a tetracycline transactivator (TTA) as a cell-based model of effects of mutant amyloid toxicity. Co-transfected (transfected) or TTA-transfected (control) N2A cells were pre-incubated ± nicotinamide...
adenine dinucleotide (NAD⁺) and oxygen consumption rates (OCR) measured. Transfected N2A cells (no exogenous NAD⁺; blue dashed line) had decreased maximal OCR when challenged with uncoupler carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) and pyruvate, compared to control cells + NAD⁺ (24% decrease; Figure 1, red solid line); or control cells without exogenous NAD⁺ addition (18% decrease; Figure 1, red dashed line). This OCR deficit (Figure 1, blue dashed line) could be ameliorated if exogenous NAD⁺ was present (27% increase; Figure 1, blue solid line). Control N2A cultures had similar OCR regardless of NAD⁺ addition (Figure 1, red solid versus red dashed line). These experiments suggest that deficiencies in NAD⁺ levels could play a role in mitochondrial respiratory dysfunction in transgenic mice expressing this mutation in vivo [14] and could be corrected with added NAD⁺.

Decreased full-length mutant human Amyloid Precursor protein (APP) levels in brain of NMN treated transgenic mice

Forebrain homogenates were assessed for relative transgene-derived full-length APP expression in both APP(swe)/PS1(ΔE9) transgenic (AD-Tg) and non-transgenic (NTG) mice (3 months). There were significantly (p < 0.05) increased mutant full-length APP levels in the brain homogenates from the AD-Tg mice regardless of treatment when compared to non-transgenic littermates. There was a significant (p ≤ 0.05) decrease (38%) in full-length mutant APP levels in brain homogenates of AD-Tg mice treated with NMN as compared to AD-Tg vehicle-treated mice (Figure 2).

Oxygen consumption deficits in brain mitochondria isolated from AD-Tg mice are reversed by nicotinamide mononucleotide (NMN)

In a previous study, we determined that brain mitochondrial ADP-stimulated OCR were significantly deficient in 3 months old male AD-Tg mice as compared to their non-transgenic littermates [14]. NAD⁺ as a cofactor for tricarboxylic acid (TCA) cycle and Complex I enzymatic reactions and deficiencies give rise to bioenergetic dysfunction. The NAD⁺ precursor nicotinamide mononucleotide (NMN) inhibits NAD⁺ degradation as well as enhancing its synthesis [27]. Therefore, to examine the potential relationship between mitochondrial respiratory dysfunction and NAD⁺ catabolism, AD-Tg and non-transgenic (NTG) mice (2 months) were given NMN or phosphate buffered saline (PBS, vehicle). Non-synaptic mitochondria were then isolated from the forebrains of male and female (3 months) AD-Tg mice and their NTG littermates. There were no significant differences in basal OCR between the transgenic and non-transgenic mice regardless of NMN treatment (Figure 3, Basal). However, following addition of ADP to initiate State 3 respiration, the AD-Tg vehicle-treated mice had significantly lower OCR (p < 0.01) compared to the NTG animals (Figure 3, ADP) recapitulating our previous study [14]. The AD-Tg vehicle-treated mice were significantly deficient (p < 0.01) in State 3 respiration as compared to the transgenic mice that received NMN treatment (Figure 3, ADP). Interestingly, the AD-Tg NMN-treated mice had significantly increased (p < 0.01) OCR as compared to the non-transgenic animals (Figure 3, ADP). Following oligomycin addition reducing the rate of O₂ consumption to that of State 4 respiration, there was no

![Figure 1 OCR in APPswe/PS1ΔE9-overexpressing N2A hippocampal neuroblastoma cells (blue lines) and control transfected cells (red lines). Baseline-normalized oxygen consumption rates (OCR) of N2A neuroblastoma cells exposed to successive additions of mitochondrial respiratory modulators (arrows) are shown. Cells received 1 μg/ml oligomycin (Oligo), 1 μM FCCP, 10 mM pyruvate (Pyr), and 1 μM antimycin A (Ant A). Subsets of the cells (solid lines) were pre-incubated with 10 mM nicotinamide adenine dinucleotide (NAD⁺) prior to measurements while control cells (dashed lines) had no exogenous NAD⁺. Rates are normalized to the third baseline measurement point for n = 3–5 replicates per group from 2 separate cultures.

Long et al. BMC Neurology (2015) 15:19
Figure 2 Full-length, transgene-derived amyloid precursor protein (APP) levels in brain homogenates following NMN treatment. (A) Representative Western blots of homogenates isolated from the brains of AD-Tg and non-transgenic (NTG) mice (3 months) probed with 6E10 antibody. (B) Transgene-derived full-length APP (~106kD) is observed in AD-Tg mice with negligible levels in the NTG mice. Full-length APP levels (ratio of APP/β-Actin) are significantly decreased in NMN-treated transgenic (AD-Tg NMN) mice compared to AD-Tg vehicle-treated. Data are presented as the average full-length APP ± SE. N = 6 separate animals per group. *p < 0.05.

Figure 3 OCR deficits in non-synaptic brain mitochondria from mutant APP expressing mice following NMN treatment. Average OCR (pMoles/min) in non-synaptic mitochondria isolated from APP_{K661/PS1ΔE9} (AD-Tg) and non-transgenic (NTG) mouse (3 months) brain. Solid black bar (NTG vehicle control), white bar (AD-Tg vehicle control) and striped bar (AD-Tg NMN). Data are presented as the average OCR ± SE. N = 3–5 separate animals per group. *p < 0.01.
significant difference in OCR between the transgenic and non-transgenic mice regardless of treatment group (Figure 3, Oligo). Although, following addition of FCCP to assess maximal OCR there was no significant difference between NTG vehicle and AD-Tg vehicle-treated mice, the AD-Tg NMN-treated mice had significantly increased (p < 0.01) OCR as compared to both the transgenic vehicle-treated and non-transgenic animals (Figure 3, FCCP).

Histone deacetylase sirtuin1 (SIRT1) and CD38 protein levels in brain homogenates

NAD\(^+\) is utilized as an important cofactor in many metabolic reactions [28] including oxidative phosphorylation and enzymatic reactions of the TCA cycle [5], and as a substrate for enzymes including histone deacetylase sirtuin 1 (SIRT1), poly(ADP-ribose) polymerase 1 (PARP1) and NAD\(^+\) glycohydrolase CD38. We assessed brain homogenates from AD-Tg and non-transgenic NMN- and vehicle-treated mice to determine if NAD\(^+\) catabolism was due to increased SIRT1 levels. There was a significant increase (p < 0.05) in SIRT1 immunoreactivity in brain homogenates from AD-Tg mice when compared to both NTG animals as well as AD-Tg animals pre-treated with NMN (Figure 4). Although the AD-Tg mice pre-treated with NMN had lower SIRT1 immunoreactivity compared to non-NMN treated AD-Tg mice, these levels were still significantly elevated (p ≤ 0.05) as compared to NTG animals (Figure 4).

SIRT1 immunoreactivity in brain homogenates was examined to assess potential additive effects of AD transgenes in older animals (3–9 months). There was significantly (p < 0.05) increased SIRT1 immunoreactivity in the 9 months AD-Tg mice as compared with both the 3 and 6 months animals (Figure 5A, B). Further, the 6 months AD-Tg SIRT1 levels were also significantly (p ≤ 0.05) elevated compared to the 3 months AD-Tg mice (Figure 5A, B). As described above, an alternative NAD\(^+\) consumer is the NAD\(^+\) glycohydrolase CD38 (CD38). We therefore also probed

![Image](Figure 4 Immunoreactivity of SIRT1 in homogenates isolated from NTG and AD-Tg mouse brain following NMN treatment. Each lane represents a different animal. (A) Representative Western blot images. (B) Significantly increased SIRT1 levels (ratio SIRT1:GAPDH) are observed in AD-Tg (vehicle) homogenates compared to NTG vehicle-treated animals. These levels are significantly reduced (~49%) by the addition of NMN in AD-Tg mice although they remain significantly elevated. NTG SIRT1 levels normalized to GAPDH = 0.004 as presented in (B). Data are presented as the average SIRT1 ± SE. N = 6 separate animals per group. **p ≤ 0.05.)
brain homogenates from both NTG and AD-Tg mice aged 3–12 months utilizing Western blots. There was a significant increase (p < 0.05) in CD38 immunoreactivity in the 3 and 12 months AD-Tg mice as compared to age-matched NTG animals (Figure 5C,D). There was a significant decrease (p < 0.05) in CD38 immunoreactivity between 3 and 6 months AD-Tg mice (Figure 5C,D). There was no significant difference in CD38 immunoreactivity in NTG mice across the age groups examined. Although there was an overall significant difference in CD38 levels comparing genotypes (p < 0.01) or age (p < 0.01), there was no genotype x age interaction (Figure 5C, D).

**Morphological analyses of brain mitochondria from CaMK2a-mito/eYFP mice**

To begin examining potential explanations for the ameliorative benefits following in vivo addition of the NAD+ precursor NMN, we examined morphological parameters in brain tissue of mice (3 months) possessing mitochondrial-targeted fluorescent proteins in neurons (CaMK2a-mito/eYFP mice). Mitochondrial morphology has been demonstrated to influence respiration rates, calcium homeostasis and organelle transport [15,16].

Brain mitochondrial respiratory rates in CaMK2a-mito/eYFP mice have been previously determined to be similar to the rates in wildtype mice [21] and therefore can be utilized as an important tool to examine morphology. Following the same protocol for NMN treatment as described in the AD animals above, CaMK2a-mito/eYFP mice given vehicle had more fragmented neuronal mitochondria in the CA1 region of the hippocampus when compared to CaMK2a-mito/eYFP animals given NMN (Figure 6A). The CaMK2a-mito/eYFP mice given NMN had far less fragmented mitochondria, but had longer neuronal mitochondria in the CA1 region (Figure 6B).

We next examined the shape of fluorescent neuronal mitochondria in the CaMK2a-mito/eYFP mice. Shape factor is a numerical value indicating how similar a 3D shape is to a perfect sphere. Thus, a shape factor value of 1 was considered to be completely spherical whereas the closer to zero was considered to be rod-shaped. Figure 6C diagrams the relative counts comprising the shape factor value of neuronal mitochondria from NMN-treated versus vehicle-treated mice. When the shape of neuronal mitochondria in the CA1 hippocampal region were examined, there was a significant (p < 0.05) increase in rod-shaped mitochondria in NMN-treated mice compared to vehicle-treated animals (Figure 6D). There was a reciprocal decrease in spherical-shaped mitochondria in these same regions in NMN-treated mice as compared to vehicle-treated animals that were significantly (p < 0.05) altered (Figure 6D). Interestingly, there was a significant (p < 0.05) difference between rod and spherical-shaped mitochondria in the vehicle-treated mice but no significant shape difference in the
NMN-treated animals (Figure 6D). Following quantification of fluorescent neuronal mitochondria in the CA1 hippocampal regions, there was a significant difference in mitochondrial skeletal length when comparing NMN treated and vehicle treated CaMK2a-mito/eYFP mice (Figure 6E, F). The relative counts for skeletal length were sub-divided into “spherical” (0–2 μm), “rod shaped” (2.2–6 μm) and “tubular” (6.2–15 μm). The control mice had significantly (p < 0.05) increased “spherical” length mitochondria compared to the NMN treated animals (Figure 6F). Conversely, the control mice had significantly decreased “rod shaped” (p < 0.01) and “tubular” (p ≤ 0.001) length mitochondria compared to NMN treated animals (Figure 6F). There were no significant differences in the relative counts for total volume or total surface area between treatment groups (data not shown). Further, the total number of mitochondria approached significance with a trend toward less mitochondria in NMN-treated mice (p = 0.066), as compared to vehicle-treated animals (data not shown). Together, these data suggest that NMN treatment gives rise to longer mitochondria in the hippocampal sub-region examined, likely through increased fusion and/or decreased fission.

Altered Drp1 phosphorylation mediates mitochondrial fragmentation in AD-Tg mice

Mitochondrial morphology is modulated by a dynamic balance between fragmentation (fission) and formation of tubular elongated structures (fusion) (reviewed in [29,30]). Fission and fusion protein immunoreactivity was therefore examined in mitochondria isolated from the NTG and AD-Tg mice above that were given NMN or vehicle.

The dynamin-related protein 1 (DRP1) with mitochondrial fission 1 protein (Fis1) control mitochondrial

Figure 6 Changes in mitochondrial dynamics following NMN treatment in CA1 hippocampal neurons from CAMK-eYFP mice. Representative confocal images of control (A) and NMN-treated (B) neuronal mitochondria in the CA1 hippocampal sub-region. The fluorescent mitochondria appear more fragmented (see white arrows) in the control image compared to NMN treatment that clearly demonstrates more elongated mitochondria. Graphs (C, D) show the relative shape distribution and the relative mitochondrial length distribution (E, F) of different mitochondrial populations. Scale bar in panels (A) and (B) represents 5 μm. **p < 0.05; *p < 0.01.
DOI: 10.1186/1471-2379-15-19

Long et al. BMC Neurology  (2015) 15:19
Page 10 of 14

fragmentation. When DRP1 immunoreactivity was assessed in isolated brain mitochondria, there was a trend toward an increase in DRP1 immunoreactivity in AD-Tg mice as compared to NTG animals (p = 0.072) that was not changed in the NMN-treated cohort (Figure 7A, B). When DRP1 is phosphorylated at a specific serine residue (Ser616, P616-DRP1), stabilization of the outer membrane of cytoplasmic DRP1 occurs [31]. There was a significant (p < 0.05) increase in P616-DRP1 immunoreactivity in mitochondria isolated from AD-Tg mice as compared to NTG animals (Figure 7A, C). The AD-Tg mice treated with NMN had significantly (p < 0.05) decreased P616-DRP1 immunoreactivity as compared to AD-Tg vehicle-treated animals (Figure 7A, C). There was no significant difference in mitochondrial P616-DRP1 immunoreactivity between NTG animals and AD-Tg mice treated with NMN (Figure 7A, C).

OPA1 and MFN2 immunoreactivity are differentially altered in AD-Tg mice

We next examined immunoreactivity in these samples for mitofusin 2 (MFN2) and optic atrophy protein (OPA1), both associated with mediation of mitochondrial fusion.

Optic atrophy 1 (OPA1) is a dynamin-related GTPase that resides in the mitochondrial inner membrane (IMM) promoting regulation of mitochondrial fusion [32], OPA1 as an oligomeric complex in healthy mitochondria maintains cristae integrity. The oligomeric complex comprises a heterotrimer formed by integral IMM (long form ~100 kD; OPA1-L) and soluble intermembrane space (IMS, short form ~80 kD; OPA1-S) forms of OPA1. There was a significant (p < 0.05) increase in OPA1-L immunoreactivity in AD-Tg mice compared to both NTG animals and AD-Tg mice that

![Figure 7](https://example.com/figure7.png)

**Figure 7** Immunoreactivity of fission/fusion proteins in brain mitochondria isolated from mouse brain following NMN treatment. (A) Representative Western blot images of fission (DRP1 and phosphorylated form P616-DRP1) and fusion (OPA1 and MFN2) proteins. (B-F) Graphs showing quantification of the Western blots in (A). The OPA1 oligomeric complex comprises the long (L) fusogenic form and the short (S) form [32]. Voltage-dependent anion channel (VDAC) was utilized as a loading control. Data are presented as the average DRP, P616-DRP1, OPA1, OPA1S, MFN2 ± SE. N = 5–7 separate animals per group. **p < 0.05.
received NMN (Figure 7A, D). There was no significant difference in OPA1-L immunoreactivity between the NTG and AD-Tg mice that received NMN (Figure 7A, D). There was no significant difference in immunoreactivity across groups for the OPA1-S form (Figure 7A, E).

Mitofusin 2 (MFN2) also a GTPase is involved in fusion of the mitochondrial outer membrane (OMM). There were no significant differences in MFN2 levels across groups (Figure 7A, F). Taken together, these data demonstrate that the AD-Tg mice have increased mitochondrial fragmentation compared to NTG animals and also mitochondrial fusion occurring which is ameliorated in the transgenic mice given exogenous NMN.

Discussion

Alzheimer’s disease, along with other neurodegenerative diseases, has a complex multifactorial pathology with known mitochondrial deficits. This study is the first to directly examine the amelioration of NAD⁺ catabolism and changes in mitochondrial morphological dynamics in AD mouse brain utilizing the immediate precursor nicotinamide mononucleotide (NMN) as a potential therapeutic compound. At three months, the well-studied AD chimeric APP(ΔE9) mice model have mitochondrial oxygen consumption rate (OCR) deficits [14] that precede amyloid deposition and plaque formation in brain [33]. In the present study, deficiencies in OCR were successfully reversed using the same murine AD model administered NMN. In addition, NMN reduced levels of full length mutant APP in the AD-Tg mice. Further, the effects of NMN on normal mitochondrial morphology were examined using mice possessing fluorescent proteins targeted to neuronal mitochondria (CaMK2a-mito/eYFP) and demonstrate mitochondrial elongation and decreased fragmentation in NMN treated animals.

Nicotinamide (NAM) administration has been demonstrated to cross the blood–brain barrier and be converted to NAD⁺, thus increasing cellular NAD⁺ levels in the brain [34]. Further, NMN has been shown to be highly enriched in mitochondria by sub-cellular fractionation studies suggesting intramitochondrial NAD⁺ synthesis [35] and may inhibit CD38 NAD⁺ glycohydrolase activity [27,36]. Several disease/injury model studies have previously utilized NMN as a therapeutic to ameliorate NAD⁺ deficiencies. Yoshino et al. [37] reversed NAD⁺ defects in a diabetic mouse model with intraperitoneal (IP) injections of NMN (500 mg/kg body weight/day for 7 days) a higher total dosage compared to the present study. In a separate study, NAD⁺ levels were increased within 30 minutes after NMN administration (IP, 500 mg/kg body weight) directly following ischemia and reperfusion in mouse heart [9]. Further, NMN prevented decreases in NAD⁺ if injected 30 minutes prior to the insult [9]. In a cell culture model of Parkinson’s disease consisting of rotenone treated PC12 cells, NMN intervention reduced apoptosis and restored intracellular levels of NAD⁺ and ATP [11]. In the present study, we used early low dose NMN administration beginning at two months of age to prevent the OCR deficits seen previously in three months old AD-Tg mice [14].

Studies of NAD⁺ deficiencies in diabetes, hepatic steatosis, and aging have historically used the NAD⁺ salvage pathway supplements: NAM or nicotinic acid (NA) [38,39]. Nicotinic acid can bind to the GPR109A receptor, a G protein-coupled receptor that binds NA resulting in severe flushing as a side effect, making it unfavorable to most patients [39]. Alternatively, nicotinamide riboside (NR) and NMN do not bind to the GPR109A receptor and are considered to have fewer unfavorable side effects [39]. Several studies have looked at NAM and NR as possible therapeutics for Alzheimer’s disease, although none have used NMN. Liu et al. [40] administered NAM for 8 months in triple transgenic AD mice, finding NAM reduced beta amyloid (Aβ) and tau pathologies, elevated brain NAD⁺ levels, improved brain bioenergetics, and preserved mitochondrial functionality. In a separate study, Green et al. [41] treated four months old triple transgenic AD mice for 4 months, finding NAM treatment decreased tau levels and improved cognition. Similarly, when adult neurons isolated from triple transgenic AD mice aged 2 or 21 months were treated with NAM for 15 hours, NADH regenerating capacity was completely restored [42]. In a different AD disease mouse model, Gong et al. [43] treated Tg2576 animals with NR from 5–6 month of age until 10–11 months of age. NR treated mice had increased brain NAD⁺ levels, elevated Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), reduced Aβ, and reduced Beta site APP cleaving enzyme 1 (BACE1) [43]. Our present study is the first report using NMN in any AD mouse model, treating them temporally prior to amyloid deposition to focus on mitochondrial bioenergetics.

Sirtuins (SIRT 1–7) are class III histone deacetylases and NAD⁺ dependent enzymes [44]. Activation of SIRT1 mainly exerts neuroprotective actions [1] for example by deacetylating target proteins including PGC-1α, demonstrated to be deficient in human AD brain [45]. PGC-1α activation gives rise to mitochondrial biogenesis. In another study in APP/PS1 AD mice, overexpression of SIRT1 improved behavior and reduced Aβ [46]. In the present study, AD-Tg mice had significantly increased SIRT1 immunoreactivity compared to nontransgenic (NTG) mice that NMN treatment reduced (Figure 4) potentially preserving overall NAD⁺ pools for functional mitochondrial energetics.
Mitochondrial energetics in NMN treated animals could also be influenced by dynamic efficiency and the balance between fission and fusion. Mitochondrial fission is regulated by the short and long isoforms of the protein Optic atrophy 1 (Opa1), as well as Mitofusin proteins (Mfn1 and Mfn2). Long and short OPA1 isoforms are both required for fusion. There is a reduction in fusion and an increase in fragmentation when the long OPA1 isoforms are converted to the short soluble OPA1 isoforms [47]. This can be the result of a reduction in mitochondrial membrane potential and can lead to mitophagy and cellular death [47]. Mitochondrial fission is regulated by Dynamin related protein Drp1, specifically by post-translational modifications of Drp1 [18]. Short round mitochondria occur more commonly with dysfunctional mitochondria resulting from treatment with a toxin or mtDNA depletion [48]. In this study we found a significant increase in \( p^{616}\)-DRP1 immunoreactivity in AD-Tg mouse mitochondria compared to NTG and AD-Tg NMN treated animals. This would indicate AD-Tg mice might have more fission and fragmentation of mitochondria than the NTG mice. Furthermore, NMN reduced fission in the treated AD-Tg mice reverting \( p^{616}\)-DRP1 levels to those of NTG animals.

To more clearly investigate mitochondrial morphology, CA1 hippocampal sections from CaMK2α-mito/eYFP mice were examined. These bigenic mice were previously determined to have functional mitochondrial bioenergetics similar to non-transgenic littermates [21]. NMN treated CaMK2α-mito/eYFP mice had longer mitochondria and reduced fragmentation, while vehicle treated mice had a greater proportion of spherical mitochondria, possibly indicating more fusion. There were no differences in total mitochondrial volume and the NMN treated samples had slightly fewer mitochondria, suggesting, NMN reduces fission or increases fusion. Taken together, NMN treatment decreased fission (\( p^{616}\)-DRP1, AD mice) and reduced fragmentation (CaMK2α-mito/eYFP mice) suggesting a shift in dynamics from fission to fusion. This shift in dynamics could explain amelioration of mitochondrial bioenergetic deficits in the AD-Tg mice given NMN.

Conclusions

We have established a potentially promising therapeutic protocol for the use of NMN as a viable supplement to reduce the cellular NAD\(^+\) deficits found in an AD mouse model. Administration of NMN improved mitochondrial bioenergetics in an AD-Tg AD mouse model as well as reduced mitochondrial fragmentation in mice possessing fluorescent proteins targeted to neuronal mitochondria without any observable negative side effects. The present study used young AD-Tg mice that had yet to form Aβ plaques given a low dose of NMN administered every other day for one month. It remains unclear if NMN prevented the mitochondrial deficits or remediated them. Reduction of full-length mutant APP following NMN treatment may also play a role in amelioration of mitochondrial bioenergetic function. Further studies need to be performed to examine potential benefit of NMN administered to older mice with progressive disease pathology. Furthermore, it is unknown whether a higher dose of NMN or longer duration of administration would be even more beneficial. By showing NMN can improve mitochondrial bioenergetics and dynamics in the mouse brain, we conclude that NMN has the potential to be a promising therapeutic for further testing on other neurological disease models with known NAD\(^+\) deficits.

Abbreviations

\( \beta \)AD: Beta amyloid; AD: Alzheimer’s disease; AD-Tg: APP\(^{\text{swt}}\)/PS1\(^{\text{ΔE9}}\) transgenic; ALS: Amyotrophic lateral sclerosis; AMP: Adenosine monophosphate; APP: Amyloid precursor protein; APP\(^{\text{swt}}\): Amyloid precursor protein with the Swedish mutation; ATP: Adenosine triphosphate; BACE1: Beta site APP cleaving enzyme 1; CAMKKII: Calcium/calmodulin-dependent kinase II; CD38: ADP-ribosyl cyclase; DRP1: Dynamin-related protein 1; EYFP: Enhanced yellow fluorescent protein; FCCP: Carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HD: Huntington’s disease; IMM: Mitochondrial inner membrane; ICSM: Inter-membrane space; MFN1: Mitofusin 1; MFN2: Mitofusin 2; MS: Multiple sclerosis; NA: Nicotinic acid; NAD: Nicotinamide adenine dinucleotide; NAM: Nicotinamide; Nampt: Nicotinamide phosphoribosyltransferase; NMN: Nicotinamide mononucleotide; NMNAT: Nicotinamide mononucleotide adenyltransferase; NR: Nicotinamide riboside; NTG: Non-transgenic; OCR: Oxygen consumption rates; OMMA: Mitochondrial outer membrane; OPA1: Optic atrophy protein; PARP1: Poly (ADP-ribose) polymerase 1; PBS: Phosphate buffered saline; PBST: Phosphate buffered saline (PBS) with 0.1% tween-20; PCR: Polymerase chain reaction; PD: Parkinson’s disease; \( p^{616}\)-DRP1: Phospho-DRP1; PGC1α: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PS1: Mutant human presenilin 1; PS1\(^{\text{ΔE9}}\): Mutant human presenilin 1 with the delta E9; SIRT1: Siruinz 1; TCA: Tricarboxylic acid; tTA: Tetracycline-controlled transactivator protein; TTA: Tetracycline transactivator; VDAC: Voltage dependent anion channel.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

ANL performed the confocal microscopy, analyzed the morphology data, Western blots and drafted the manuscript. KD assisted with confocal microscopy and morphology analysis. AES performed the N2A cell culture experiments. TK assisted with morphology data analysis, study design and data interpretation, PSF assisted with drafting the manuscript, study design and data interpretation. RAS designed the study, performed the mitochondrial oxygen consumption and Western blotting experiments, analyzed the data and co-drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

APP(695) and PS1(ΔE9) cDNA was a kind gift from Dr. David Borchelt. The mEYFP construct was a kind gift from Dr. Krish Chandrasekaran and Dr. Tibor Kristán. We would like to thank Mary Remington for generating the DNA construct. This work was supported by grants from the VA Research Service Rehabilitation R&D REAP (RAS, PSF), Biomedical R&D CDA02 (RAS), Biomedical R&D Went BK000917 (TK), and NIH (AG031387-MA Ottinger and AES).

Author details

1. Research Service, VAMHCS, 10 North Greene Street, Baltimore, MD 21201, USA. 2. Department of Neurology, University of Maryland, School of Medicine, Baltimore, MD 21201, USA. 3. Program in Neuroscience and Cognitive Neuroscience, Baltimore, MD 21201, USA.
References

1. Scuderi C, Stecca C, Bronzulli MR, Rottoli D, Valente S, Mai A, et al. Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease. Front Pharmacol. 2014;5(89):1–8.

2. Hrowadová J, Singh N, Filas Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer’s disease. BioMed Res Int. 2014;2014:1–9.

3. Houkoop RH, Auwert J. Exploring the therapeutic space around NAD+. J Cell Biol. 2012;199(2):205–9.

4. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24:64–71.

5. Kristan T, Balan J, Schuh R, Onken M. Mitochondrial dysfunction and nicotinamide dinucleotide catabolism as mechanisms of cell death and promising targets for neuroprotection. J Neurosci Res. 2013;89(12):1946–55.

6. Owens K, Park JH, Schuh R, Kristian T. Mitochondrial Dysfunction and NAD (+) metabolism alterations in the pathophysiology of acute brain injury. Transl Stroke Res. 2013;4:618–34.

7. Liu D, Pitta M, Mattson MP. Preventing NAD+ depletion protects neurons against excitotoxicity: bioenergetic effects of mild mitochondrial uncoupling and caloric restriction. Ann N Y Acad Sci. 2008;1147:247–8.

8. Alano CC, Garner P, Yang W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ depletion is necessary and sufficient for Poly(ADP-Ribose) polymerase-1-mediated neuronal death. J Neurosci. 2010;30(9):2967–78.

9. Yamamoto T, Byun J, Zhai P, Ikeda Y, Oka S, Sadoshima J. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One. 2014;9(6):1–8.

10. Caton PW, Kiewisch J, Yapoooi MM, Holmfeld M, Sugden MC. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of mouse islet function. Diabetologia. 2011;54(12):3883–92.

11. Lu L, Tang L, Wei W, Hong Y, Chen H, Ying W, et al. Nicotinamide mononucleotide improves energy activity and survival rate in an in vitro model of Parkinson’s disease. Exp Ther Med. 2014;8(3):943–50.

12. Wu MF, Yin JH, Hwang CS, Tang CM, Yang DI. NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons. Free Radic Res. 2014;48(7):794–805.

13. Pittelli M, Felici R, Pitoci V, Giovannelli L, Bigagli E, Cialdi F, et al. Pharmacological effects of exogenous NAD on mitochondria bioenergetics, DNA repair, and apoptosis. Mol Pharmacol. 2011;80(6):1136–46.

14. Schuh RA, Jackson KC, Schlappal AE, Spangenberg EE, Ward CE, Park JH, et al. Mitochondrial oxygen consumption deficits in skeletal muscle isolated from an Alzheimer’s disease-relevant murine model. BMC Neurosci. 2014;15(2):12.

15. Szabadi G, Simoni AM, Chami M, Wlekowski MR, Youle RJ, Rizzuto R. Drp1-dependent division of the mitochondrial network blocks intraorganellar Ca2+ waves and protects against Ca2+ mediated apoptosis. Mol Cell. 2004;16(1):59–68.

16. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet. 2009;18(2):R69–76.

17. Escobar-Henriques M, Anton F. Mechanistic perspective of mitochondrial fusion: tubulation vs. fragmentation. Biochim Biophys Acta. 2013;1833(1):162–75.

18. Otera H, Ishihara N, Milam K. New insights into the function and regulation of mitochondrial fission. Biochim Biophys Acta. 2013;1833(3):1255–68.

19. Reddy PH. Inhibitors of mitochondrial fission as a therapeutic strategy for diseases with oxidative stress and mitochondrial dysfunction. J Alzheimer’s Dis. 2014;40(2):245–56.

20. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274(5293):1678–83.

21. Chandrasekaran K, Hazeltin JL, Wang Y, Fiskum G, Kristian T. Neuron-specific conditional expression of a mitochondrial targeted fluorescent protein in mice. J Neurosci. 2006;26(51):13123–7.

22. Sims NR. Rapid isolation of metabolically active mitochondria from rat brain and subregions using percholl density centrifugation. J Neurochem. 1990;55(6):659–707.

23. Kristan T, Weatherby T, Bates T, Fiskum G. Heterogeneity of the calcium-induced permeability transition in isolated non-synaptic brain mitochondria. J Neurochem. 2002;83(1):297–308.

24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.

25. Rogers GW, Brand MD, Petroleum S, Ashok D, Elorza AA, Ferrick DA, et al. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS One. 2011;6(7):e21746.

26. Owens K, Park JH, Gourley S, Jones H, Kristian T. Mitochondrial dynamics: cell-type and hippocampal region specific changes following global cerebral ischemia. J Bioenerg Biomembr. 2014;46:1991–90.

27. Balan IS, Fiskum G, Kristian T. Visualization and quantification of NAD(H) in brain sections by a novel histo-enzymatic nitrotetrazolium blue staining technique. Brain Res. 2010;1316:12–9.

28. Brennan AM, Connor JA, Shuttleworth CW. NADPH fluorescence transients after synaptic activity in brain slices: predominant role of mitochondrial function. J Cereb Blood Flow Metab. 2006;26(11):1389–406.

29. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26(6):11–23.

30. Chatunvedi RK, Beal MF. Mitochondrial diseases of the brain. Free Radic Biol Med. 2013;63:1–29.

31. Chang CR, Backstone C. Dynamic regulation of mitochondrial fission through modification of the dynamin-related protein Drp1. Ann N Y Acad Sci. 2010;1201:34–9.

32. Ramonet D, Perier C, Recasens A, Dehay B, Bove J, Costa V, et al. Optic atrophy 1 mediates mitochondria remodeling and dopaminergic neurodegeneration linked to complex I deficiency. Cell Death Differ. 2013;20(1):77–85.

33. Machova E, Rudajev V, Smykova H, Kolivsto H, Tanha L, Dolezal V. Functional cholinergic damage develops with amyloid accumulation in young adult APPsw/PS1dE9 transgenic mice. Neurobiol Dis. 2010;38(1):27–35.

34. Spector R, Johanson CE. Vitamin transport and homeostasis in mammalian brain: focus on Vitamins B and E. J Neurochem. 2007;103(2):425–38.

35. Formentini L, Moroni F, Chiarugi A. Detection and pharmacological modulation of nicotinamide mononucleotide (NMN) in vitro and in vivo. Biochim Pharmacol. 2009;77(10):1612–20.

36. Snell CR, Snell PH, Richards CD. Degradation of NAD by synaptosomes and its inhibition by nicotinamide mononucleotide: implications for the role of NAD as a synaptic modulator. J Neurochem. 1984;43(6):1610–5.

37. Yoshino J, Mills KF, Yoon JI, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36.

38. Yang SJ, Choi JM, Kim L, Park SE, Rhee EI, Lee WY, et al. Nicotinamide improves glucose metabolism and affects the hepatic NAD/sirtuin pathway in a rodent model of obesity and type 2 diabetes. J Nutr Biochem. 2014;25(1):66–72.

39. Cantó C, Houkoop R, Pirinen E, Youn D, Oosterveer M, Cen Y, et al. The NAD(+)-precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet induced obesity. Cell Metab. 2012;15(6):838–47.

40. Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, et al. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy process. Neurobiol Aging. 2013;34(6):1564–80.

41. Green KN, Steffen JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008;28(84):11500–10.

42. Ghosh D, LeVault K, Barnett A, Brewer G. A reversible early oxidized redox state that precedes macromolecular ROS damage in aging transgenic and 3x Tg-AD mouse neurons. J Neurosci. 2012;32(17):5821–32.

43. Gong B, Pan Y, Vampati P, Zhao W, Kruble L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated...
receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging. 2013;34(6):1581–8.

44. Rehan L, Laszki-Szczachor K, Sobieszczanska M, Polak-Jonkisz D. SIRT1 and NAD as regulators of ageing. Life Sci. 2014;105(1–2):1–6.

45. Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, et al. PGC-1α expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol. 2009;66(3):352–61.

46. Donmez G, Wang D, Cohen DE, Guarenre L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010;142(2):320–32.

47. Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014;505(7483):335–43.

48. Karbowski M, Youle RJ. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ. 2003;10(8):870–80.